1. Studies of international regulatory guidelines on safety pharmacology;Bass,2003
2. ICH Draft Consensus Guideline, S7B Safety Pharmacology Studies for Assessing the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals (2003). US Department of Health and Human Services, FDA; http://www.fda.gov/cder/guidance/4970dft.PDF.
3. ICH Harmonized Tripartite Guideline, S7A Safety Pharmacology Studies for Human Pharmaceuticals (2001). US Department of Health and Human Services, FDA; http://www.fda.gov/cder/guidance/P266_27807.
4. Status of safety pharmacology in the pharmaceutical industry—1993;Kinter;Drug Development Research,1994
5. Safety pharmacology and risk assessment;Kinter;Fundamental and Clinical Pharmacology,2002